Cevian Capital Slightly Lifts Stake in Smith & Nephew
End of Quarter Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Smith & Nephew Snats ( (SNN) ) has issued an announcement.
Cevian Capital II G.P. Limited, acting through its investment funds, modestly increased its stake in Smith & Nephew plc on 25 June 2026, according to a disclosure filed with regulators and completed on 29 June 2026. Its aggregate holding rose from 13.056468% to 13.206621% of voting rights, equivalent to 111,788,454 shares held via nominee Aurora Nominees Limited on behalf of UBS AG as custodian.
The change reflects a small increment in the voting rights held through Cevian Capital II Master Fund L.P., while the Co-Investment – Series P L.P. position remained unchanged. Although the increase did not trigger a new regulatory notification threshold, it underscores the continued presence of activist investor Cevian among Smith & Nephew’s largest shareholders, a factor closely watched by stakeholders given the potential influence on governance and strategic direction.
The most recent analyst rating on (SNN) stock is a Hold
with a $30.00 price target.
To see the full list of analyst forecasts on Smith & Nephew Snats stock,
see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock,
click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company listed in London, best known for its orthopaedics, sports medicine, and advanced wound management products. The group operates globally, supplying medical devices and therapies to hospitals and clinicians, and is a longstanding constituent of major healthcare and blue-chip equity indices.
Average Trading Volume: 1,186,899
Technical Sentiment Signal: Hold
Current Market Cap: $12.73B
For detailed information about SNN stock, go to TipRanks’ Stock Analysis page.
